The poor absorption of conventional QT limits its bioavailability and biological activity
These changes are generally beneficial, contributing to improved insulin sensitivity and reduced cardiovascular risk, though they are consequences of weight loss rather than direct drug effects
While some in-vitro (test tube) and animal studies suggest that copper peptides may act as a mild DHT blocker by inhibiting the 5-alpha reductase enzyme, it is important to note that clinical human data is still evolving, and it is not as potent as prescription DHT blockers (like Finasteride)
Modifiable factors encompass smoking, excessive alcohol consumption, insomnia, hypertension and sympathomimetic drug utilization (e.g., cocaine), with smoking and hypertension exerting the most pronounced influence
Orforglipron will likely be available within 12-18 months with no food or water restrictions